A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)

• Ian Mcgowan ,

  * E-mail: imcgowan@pitt.edu

  Affiliations University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, Microbicide Trials Network, Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America

  ⨯
• Craig Hoesley,

  Affiliation University of Alabama, Birmingham, Alabama, United States of America

  ⨯
• Ross D. Cranston,

  Affiliation University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America

  ⨯
• Philip Andrew,

  Affiliation FHI 360, Research Triangle Park, Durham, North Carolina, United States of America

  ⨯
• Laura Janocko,

  Affiliation Microbicide Trials Network, Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America

  ⨯
• James Y. Dai,

  Affiliations University of Washington, Seattle, Washington, United States of America, Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• Alex Carballo-Dieguez,

  Affiliation Columbia University, New York, New York, United States of America

  ⨯
• Ratiya Kunjara Na Ayudhya,

  Affiliation Microbicide Trials Network, Magee-Womens Research Institute, Pittsburgh, Pennsylvania, United States of America

  ⨯
• Jeanna Piper,

  Affiliation Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

  ⨯
• Florian Hladik,

  Affiliations University of Washington, Seattle, Washington, United States of America, Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• Ken Mayer

  Affiliation Fenway Health, Boston, Massachusetts, United States of America

  ⨯